I期非小细胞肺癌临床结局预测放射组学模型的开发与验证
回顾性分析147例手术训练队列与295例立体定向消融放疗验证队列的增强CT影像,提取12个放射组学特征并用随机生存森林建模。含峰度和灰度共生矩阵同质性2的两特征模型在训练集可显著风险分层并独立预测总生存,验证集风险指数与总生存、远处转移显著相关。
要点
- 两特征放射组学模型可用于I期NSCLC治疗前风险分层。
- 模型在手术训练集和立体定向消融放疗验证集均预测总生存。
- 验证集风险指数与远处转移显著相关,区域复发仅边缘显著。
核心结论
- 放射组学模型可较准确预测I期NSCLC多项临床结局并实现治疗前风险分层,有助于按个体风险选择治疗。
研究设计与样本
- 回顾性分析增强CT影像,训练队列147例接受手术,独立验证队列295例接受立体定向消融放疗。
- 提取12个放射组学特征,采用随机生存森林基于生存相关性建模并生成死亡风险指数。
主要发现
- 训练集中最优随机生存森林模型含峰度和灰度共生矩阵同质性2两个特征,风险分层log-rank P < .0001。
- 训练集中校正年龄、肿瘤体积、组织学类型和Karnofsky体能状态后,模型仍为总生存独立预测因子(HR 1.27;P < 2e-16)。
- 验证集中死亡风险指数与总生存显著相关(log-rank P = .0173;HR 1.02,P = .0438)。
- 验证集中风险指数与远处转移显著相关(log-rank P < .05;HR 1.04,P = .0407),区域复发单因素分析仅边缘显著(log-rank P < .05;HR 1.04,P = .0617)。
临床怎么用
- 对I期NSCLC患者可基于增强CT提取峰度和灰度共生矩阵同质性2构建放射组学模型,辅助治疗前风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop and validate a radiomics signature that can predict the clinical outcomes for patients with stage I non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: We retrospectively analyzed contrast-enhanced computed tomography images of patients from a training cohort (n = 147) treated with surgery and an independent validation cohort (n = 295) treated with stereotactic ablative radiation therapy. Twelve radiomics features with established strategies for filtering and preprocessing were extracted. The random survival forests (RSF) method was used to build models from subsets of the 12 candidate features based on their survival relevance and generate a mortality risk index for each observation in the training set. An optimal model was selected, and its ability to predict clinical outcomes was evaluated in the validation set using predicted mortality risk indexes. RESULTS: The optimal RSF model, consisting of 2 predictive features, kurtosis and the gray level co-occurrence matrix feature homogeneity2, allowed for significant risk stratification (log-rank P < .0001) and remained an independent predictor of overall survival after adjusting for age, tumor volume and histologic type, and Karnofsky performance status (hazard ratio [HR] 1.27; P < 2e-16) in the training set. The resultant mortality risk indexes were significantly associated with overall survival in the validation set (log-rank P = .0173; HR 1.02, P = .0438). They were also significant for distant metastasis (log-rank P < .05; HR 1.04, P = .0407) and were borderline significant for regional recurrence on univariate analysis (log-rank P < .05; HR 1.04, P = .0617). CONCLUSIONS: Our radiomics model accurately predicted several clinical outcomes and allowed pretreatment risk stratification in stage I NSCLC, allowing the choice of treatment to be tailored to each patient's individual risk profile.
引用
- Yu W, Tang C, Hobbs BP, et al. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29246722. doi:10.1016/j.ijrobp.2017.10.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。